PECAM1 and systemic lupus erythematosus: Astonishingly, similar results with a clear decrease in the proliferation capacity of CD31+ and CD31− memory Tregs with age and a significant difference in the slopes of the regression lines (p < 0.01) between treated and untreated SLE patients were also observed (Fig. 7a).